August 21, 2023 01:24 PM EDT

FDA sets October adcomm to discuss full approval for Amgen’s Lumakras to treat second-line lung cancer

Lia DeGroot

The FDA will convene its oncology advisory committee in October to discuss Lumakras, Amgen’s KRAS-inhibiting oral medication as a second-line treatment for KRAS G12C-mutated non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA sets October adcomm to discuss full approval for Amgen’s Lumakras to treat second-line lung cancer

Lia DeGroot

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Tang Capital’s Concentra bids for Singular Genomics days after Deerfield offer

Breaking down silos with a new quantitative approach to drug development

FDA sets Oc­to­ber ad­comm to dis­cuss full ap­proval for Am­gen’s Lumakras to treat sec­ond-line lung can­cer

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA sets October adcomm to discuss full approval for Amgen’s Lumakras to treat second-line lung cancer